Italian scientific excellence is opening new possibilities for families living with Duchenne muscular dystrophy. Givinostat, developed by Milan’s Italfarmaco and marketed as Duvyzat, has won the 2026 Prix Galien Italia in the rare diseases category. Presented in Turin on November 3, the recognition celebrates a medicine that translates Italian research into a treatment capable of slowing functional decline.
Behind this achievement stands a company founded in Milan in 1938. Across 88 years, Italfarmaco has combined its family heritage with sustained investment in pharmaceutical innovation. Givinostat reflects that commitment, bringing together Italian scientists, physicians, patient organizations, and international research teams around a shared goal: helping children preserve abilities that shape everyday life.
